Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

28 Oct 2015

Hospi introduces Macy Catheter Tray at ACEP annual meeting

Hospi Corporation, a patient-centric medical device company, today introduced the Macy Catheter Tray, designed to enable rapid administration of medications or fluids to patients when intravenous (IV) or oral administration is difficult. The Macy Catheter is designed to provide a bridge or alternative to IV access, to decrease hospital admissions and to facilitate discharge of patients.

26 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

23 Oct 2015

Chemotherapy-induced nausea and vomiting most common distressing symptoms in majority of cancer patients

Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc., found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live.

20 Oct 2015

New breakthrough advances our understanding of how brain detects, prevents dehydration

Scientists at the Research Institute of the McGill University Health Centre (RI-MUHC) and Duke University have made a breakthrough that advances our understanding of how the brain detects and prevents dehydration.

16 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States.

14 Oct 2015

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

The Scottish Medicines Consortium has today announced that Xofigo has been accepted for use within NHS Scotland for the treatment of adult patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

13 Oct 2015

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

9 Oct 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.

9 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Gut microbiome can play significant role in the body's response to gluten

Investigators interested in celiac disease, a chronic gastrointestinal disorder caused by an immunologic response to the ingestion of gluten, have wondered why only 2% to 5% of genetically susceptible individuals develop the disease.

8 Oct 2015

New guidance statement on palliative care to be presented at 2015 Palliative Care in Oncology Symposium

A new guidance statement from the American Society of Clinical Oncology and the American Academy of Hospice and Palliative Medicine is being presented for the first time at the 2015 Palliative Care in Oncology Symposium in Boston.

7 Oct 2015

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

While emphasis is often placed on keeping athletes and outdoor enthusiasts properly hydrated, too much water can be just as dangerous. Exercise-associated hyponatremia (EAH), also known as water intoxication, results in an extreme, and potentially fatal, sodium imbalance.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Vomiting News and Research

Further Reading

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Hospi introduces Macy Catheter Tray at ACEP annual meeting

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

New combination treatment approved by FDA for metastatic pancreatic cancer

Chemotherapy-induced nausea and vomiting most common distressing symptoms in majority of cancer patients

New breakthrough advances our understanding of how brain detects, prevents dehydration

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Gut microbiome can play significant role in the body's response to gluten

New guidance statement on palliative care to be presented at 2015 Palliative Care in Oncology Symposium

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News